TY - JOUR T1 - Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e25 LP - e25 DO - 10.1136/annrheumdis-2018-213044 VL - 78 IS - 4 AU - Fabrizio Cantini AU - Maurizio Benucci Y1 - 2019/04/01 UR - http://ard.bmj.com/content/78/4/e25.abstract N2 - We are grateful to Scherlinger and Schaeverbeke for their reply to our letter.1We would like to remind that in our letter we raised several concerns regarding the low grade of evidence supporting recommendation 6 on the switching procedure, as reported in the recently published recommendations for the use of biosimilars in rheumatology practice.2 3 We believe that international recommendations should be based on solid bases, and, as underlined in our letter, by analysis of the existing literature, the evidence of such strategy in terms of efficacy, safety, retention rate and also economic advantages is poor. In particular, the colleagues focus their remarks on reduced bio-etanercept … ER -